Global Orthobiologics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

Global Orthobiologics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Healthcare
  • Upcoming Report
  • May 2025
  • Global
  • 270 页面
  • 桌子數: 220
  • 图号: 60

Global Orthobiologics Market

市场规模(十亿美元)

CAGR :  % Diagram

Chart Image USD 9.37 Billion USD 14.82 Billion 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size (Base Year)
USD 9.37 Billion
Diagram Market Size (Forecast Year)
USD 14.82 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • XTANT MEDICAL
  • ArthrexInc.
  • SeaSpine
  • NuVasiveInc.
  • Bioventus

Global Orthobiologics Market Segmentation, By Product (Demineralized Bone Matrix (DBM), Allograft, Bone Morphogenetic Protein (BPM0), Viscosupplementation Products, Synthetic Bone Substitutes, and Others), Application (Osteoarthritis and DegenerativeArthritis, Spinal Fusion, Fracture Recovery, Soft Tissue Injuries, and Maxillofacial and Dental Applications), Type (Knee, Ankle, Hip, Wrist and Shoulder, Spine, and Others), and End-User (Hospitals and Ambulatory Centers, Research and Academic Institute, and Dental Clinics) - Industry Trends and Forecast to 2032

Orthobiologics Market Z

Orthobiologics Market Size

  • The global orthobiologics market size was valued atUSD 9.37 billion in 2024and is expected to reachUSD 14.82 billion by 2032, at aCAGR of 5.90%during the forecast period
  • This growth is driven by factors such as the increasing prevalence of musculoskeletal disorders, rising demand for minimally invasive surgical procedures, and advancements in stem cell and platelet-rich plasma therapies

Orthobiologics Market Analysis

  • The global orthobiologics market is expanding as patients increasingly opt for minimally invasive procedures and regenerative therapies, driven by their safer and more effective outcomes compared to traditional surgical methods
  • Innovations in stem cell therapy and platelet-rich plasma technologies are playing a pivotal role in this growth, offering faster recovery and improved healing, making them increasingly popular among both healthcare providers and patients
  • North America is expected to dominate the orthobiologics market with 46.07% share due to strong healthcare system and high demand for orthopedic treatments
  • Asia-Pacific is expected to be the fastest growing region in the Orthobiologics market during the forecast period with 7.09% share due to rising aging population and an increase in orthopedic surgeries
  • The Viscosupplementation Products segment is expected to dominate the Orthobiologics market with the largest share of 40.5% in 2025 due to the increasing prevalence of osteoarthritis and the growing demand for non-surgical treatment options. Viscosupplementation, which involves the injection of hyaluronic acid into the joints, helps alleviate pain, improve mobility, and enhance the quality of life for patients suffering from joint degeneration

Report Scope and Orthobiologics Market Segmentation

Attributes

Orthobiologics Key Market Insights

Segments Covered

  • By Product: Demineralized Bone Matrix (DBM), Allograft, Bone Morphogenetic Protein (BPM0, Viscosupplementation Products, Synthetic Bone Substitutes, and Others
  • By Application: Osteoarthritis and Degenerative Arthritis, Spinal Fusion, Fracture Recovery, Soft Tissue Injuries, and Maxillofacial and Dental Applications
  • By Type: Knee, Ankle, Hip, Wrist and Shoulder, Spine, and Others
  • By End User: Hospitals and Ambulatory Centers, Research and Academic Institute, and Dental Clinics

Countries Covered

North America

  • U.S.
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • U.K.
  • Netherlands
  • Switzerland
  • Belgium
  • Russia
  • Italy
  • Spain
  • Turkey
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of Asia-Pacific

Middle East and Africa

  • Saudi Arabia
  • U.A.E.
  • South Africa
  • Egypt
  • Israel
  • Rest of Middle East and Africa

South America

  • Brazil
  • Argentina
  • Rest of South America

Key Market Players

  • XTANT MEDICAL (U.S.)
  • Arthrex, Inc. (U.S.)
  • SeaSpine (U.S.)
  • NuVasive, Inc. (U.S.)
  • Bioventus (U.S.)
  • Kuros Biosciences (Switzerland)
  • K2M, Inc. (U.S.)
  • RTI Surgical Holdings, Inc. (U.S.)
  • Orthofix Holdings, Inc. (U.S.)
  • Globus Medical Inc (U.S.)
  • Harvest Technologies (U.S.)
  • Zimmer Biomet (U.S.)
  • Stryker (U.S.)
  • Medtronic (Ireland)
  • DePuy Synthes (U.S.)
  • Sanofi (France)
  • SEIKAGAKU CORPORATION (Japan)
  • Locate Bio Ltd. (U.K.)
  • MTF Biologics (U.S.)
  • Alphatec Spine, Inc. (U.S.)
  • Exactech, Inc. (U.S.)

Market Opportunities

  • Unmet Need in Scar Tissue Prevention
  • High Injury Rates in Women and Youth Athletes

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Orthobiologics Market Trends

“Growing Popularity of Regenerative Medicine in Orthobiologics”

  • The increasing adoption of regenerative medicine in orthobiologics is one of the most significant trends in the market today
  • Regenerative treatments are gaining popularity due to their ability to promote natural healing by stimulating tissue repair and regeneration
  • Stemcell therapies, platelet-rich plasma, and growth factor treatments are widely used to treat orthopedic injuries and conditions such as osteoarthritis, tendon injuries, and fractures
  • The use of biologics to enhance healing processes is seen as a promising alternative to traditional surgical procedures, reducing recovery time and improving patient outcomes
    • For instance, platelet-rich plasma therapy is being increasingly adopted in sports medicine to speed up recovery in athletes and prevent the need for invasive surgery
  • In conclusion, the growing demand for non-invasive treatments and the advancements in tissue engineering are expected to drive the continued expansion of regenerative orthobiologics in the coming years

Orthobiologics Market Dynamics

Driver

“Rising Demand for Minimally Invasive Treatments”

  • The demand for minimally invasive treatments is driving the growth of the orthobiologics market due to faster recovery and reduced complications
  • Technologies like platelet-rich plasma and stem cell injections offer non-surgical solutions for tissue regeneration and healing
  • Orthobiologic therapies are particularly effective in treating joint pain, fractures, and soft tissue injuries, gaining traction in both clinical and sports settings
  • Patients are increasingly seeking these therapies due to their ability to expedite recovery time compared to traditional surgery
    • For instance, professional athletes are opting for platelet-rich plasma injections to speed up recovery from injuries and return to their sport quickly
  • In conclusion, s awareness and technology improve, the demand for orthobiologic treatments will continue to rise, supporting market growth

Opportunity

“Expanding Applications in Sports Medicine”

  • Sports medicine offers a major opportunity for growth in the orthobiologics market, with increasing demand for faster recovery solutions
  • Orthobiologic therapies like platelet-rich plasma and stem cell injections have proven effective in treating sports-related injuries such as tendonitis, ligament tears, and cartilage damage
  • These therapies promote natural healing, reduce re-injury risk, and allow athletes to return to their sport quickly
    • For instance, professional athletes and sports teams have successfully used orthobiologic therapies to speed up recovery and improve performance
  • Growing clinical trials and research support the efficacy of these treatments, leading to increased demand in the sports medicine sector
  • In conclusion, as acceptance continues to rise, the orthobiologics market is expected to expand with more innovation and growth opportunities in this field

Restraint/Challenge

“High Treatment Costs and Limited Insurance Coverage”

  • A major challenge in the orthobiologics market is the high cost of treatment, making it less accessible to a wide range of patients
  • Therapies like stem cell therapy and platelet-rich plasma require advanced equipment, skilled practitioners, and specialized procedures, all contributing to the high costs
  • Many insurance providers do not cover these treatments, categorizing them as experimental or elective, which limits access for patients
    • For instance, patients who cannot afford out-of-pocket expenses may be reluctant to choose these therapies, slowing market growth
  • The high costs and limited coverage are also a barrier in regions with less-developed healthcare systems, hindering wider adoption of orthobiologic treatments
  • In conclusion, better insurance coverage and affordability are achieved, the growth of the orthobiologics market will face financial constraints

Orthobiologics Market Scope

The market is segmented on the basis of product, application, type, and end user.

Segmentation

Sub-Segmentation

By Product

  • Demineralized Bone Matrix (DBM)
  • Allograft
  • Bone Morphogenetic Protein (BPM0)
  • Viscosupplementation Products
  • Synthetic Bone Substitutes
  • Others

By Application

  • Osteoarthritis and Degenerative Arthritis
  • Spinal Fusion
  • Fracture Recovery
  • Soft Tissue Injuries
  • Maxillofacial and Dental Applications

By Type

  • Knee
  • Ankle
  • Hip
  • Wrist and Shoulder
  • Spine
  • Others

By End User

  • Hospitals and Ambulatory Centers
  • Research and Academic Institute
  • Dental Clinics

In 2025, the viscosupplementation products segment is projected to dominate the market with a largest share in product segment

The viscosupplementation products segment is expected to dominate the orthobiologics market with the largest share of 40.5% in 2025 due to the increasing prevalence of osteoarthritis and the growing demand for non-surgical treatment options. Viscosupplementation, which involves the injection of hyaluronic acid into the joints, helps alleviate pain, improve mobility, and enhance the quality of life for patients suffering from joint degeneration. As a minimally invasive procedure, it is preferred by both patients and healthcare providers for its ability to delay or avoid the need for more invasive surgeries.

The spinal fusion segment is expected to account for the largest share during the forecast period in technology segment

In 2025, the spinal fusion segment is expected to dominate the market with the largest market share of 50.05% due to the increasing prevalence of spinal disorders, such as degenerative disc disease and spinal arthritis. Spinal fusion procedures, which involve the use of biologics to promote the healing of spinal bones, are widely adopted to treat conditions that cause chronic back pain or instability. The rising aging population, along with an increase in lifestyle-related conditions, is driving the demand for these procedures. Additionally, advancements in spinal fusion technologies, including the use of orthobiologics for faster recovery and enhanced outcomes, are contributing to the segment's growth.

Orthobiologics Market Regional Analysis

“North America Holds the Largest Share in the Orthobiologics Market”

  • North America is the leading region in the global orthobiologics market, with 46.07% share due to strong healthcare system and high demand for orthopedic treatments
  • The U.S. is the largest market due to its advanced healthcare infrastructure and high prevalence of musculoskeletal conditions
  • Significant investment in research and development by both international and domestic companies has introduced advanced therapies to the region
  • Reimbursement policies that support the use of orthobiologics in medical procedures encourage widespread adoption across various healthcare settings
  • The region’s focus on innovation, along with major research universities, continues to drive the growth of new orthobiologic treatments

“Asia-Pacific is Projected to Register the Highest CAGR in the Orthobiologics Market”

  • The Asia Pacific region is experiencing rapid growth in the orthobiologics market due to rising aging population and an increase in orthopedic surgeries
  • Countries such as China and India are leading this growth, with a growing awareness of the benefits of orthobiologic treatments
  • The region is benefitting from improvements in medical infrastructure and healthcare access, which is facilitating broader adoption of these therapies
  • Rising healthcare expenditures and government initiatives are enhancing the availability of advanced treatments and technologies
  • Local manufacturers are expanding their presence and developing products to meet both domestic and international market demands

Orthobiologics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

  • XTANT MEDICAL (U.S.)
  • Arthrex, Inc. (U.S.)
  • SeaSpine (U.S.)
  • NuVasive, Inc. (U.S.)
  • Bioventus (U.S.)
  • Kuros Biosciences (Switzerland)
  • K2M, Inc. (U.S.)
  • RTI Surgical Holdings, Inc. (U.S.)
  • Orthofix Holdings, Inc. (U.S.)
  • Globus Medical Inc (U.S.)
  • Harvest Technologies (U.S.)
  • Zimmer Biomet (U.S.)
  • Stryker (U.S.)
  • Medtronic (Ireland)
  • DePuy Synthes (U.S.)
  • Sanofi (France)
  • SEIKAGAKU CORPORATION (Japan)
  • Locate Bio Ltd. (U.K.)
  • MTF Biologics (U.S.)
  • Alphatec Spine, Inc. (U.S.)
  • Exactech, Inc. (U.S.)

Latest Developments in Global Orthobiologics Market

  • ​In March 2023, the orthobiologics market concluded on a positive note despite challenges like staffing shortages, supply chain constraints, and inflation. Anticipated growth in 2023 is expected to be driven by the resurgence of elective procedures and strategic initiatives by key industry players. Key focus areas include reshaping the competitive landscape, advancements in osteobiologics, and shifts in the U.S. bone replacement and sports medicine markets
  • ​In September 2024, Temple OrthoBiologics launched with a mission to revolutionize sports medicine by preventing scar tissue formation—a long-standing challenge in orthopedic recovery. Their flagship product, TX-33, is an intra-articular treatment combining advanced biomaterials and targeted drug delivery, aimed at enhancing tissue repair post-injury or surgery
  • ​In August 2023, the American Academy of Orthopaedic Surgeons (AAOS) highlighted the potential of orthobiologics—treatments utilizing biological substances like platelet-rich plasma—to offer less invasive options for musculoskeletal conditions such as osteoarthritis and tendinopathies. These therapies aim to alleviate pain, reduce inflammation, and enhance healing, potentially delaying or avoiding the need for surgery
  • ​In February 2023, projections indicated that the global orthobiologics market, valued at approximately USD 6.5 billion in 2022, is expected to reach USD 10.3 billion by 2030, growing at a CAGR of 5.9%. This growth is driven by increased product launches, rising prevalence of orthopedic conditions, and advancements in biologic materials. Bone allografts are anticipated to maintain a leading market share due to their effectiveness in procedures like spinal fusion. North America is projected to remain the dominant regional market, supported by a strong presence of key industry players and favorable reimbursement policies


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

市场是基于 Segmentation, By Product (Demineralized Bone Matrix (DBM), Allograft, Bone Morphogenetic Protein (BPM0), Viscosupplementation Products, Synthetic Bone Substitutes, and Others), Application (Osteoarthritis and DegenerativeArthritis, Spinal Fusion, Fracture Recovery, Soft Tissue Injuries, and Maxillofacial and Dental Applications), Type (Knee, Ankle, Hip, Wrist and Shoulder, Spine, and Others), and End-User (Hospitals and Ambulatory Centers, Research and Academic Institute, and Dental Clinics) - Industry Trends and Forecast to 2032 进行细分的。
在2024年,Global Orthobiologics Market的规模估计为9.37 USD Billion美元。
Global Orthobiologics Market预计将在2025年至2032年的预测期内以CAGR 5.9%的速度增长。
市场上的主要参与者包括XTANT MEDICAL ,ArthrexInc. ,SeaSpine ,NuVasiveInc. ,Bioventus ,Kuros Biosciences ,K2MInc. ,RTI Surgical HoldingsInc. ,Orthofix HoldingsInc. ,Globus Medical Inc ,Harvest Technologies ,Zimmer Biomet ,Stryker ,Medtronic ,DePuy Synthes ,Sanofi ,SEIKAGAKU CORPORATION ,Locate Bio Ltd. ,MTF Biologics ,Alphatec SpineInc. ,ExactechInc. 。
该市场报告涵盖North America的数据。
Testimonial